 BASKING RIDGE, N.J., Nov. 02, 2020 GLOBE NEWSWIRE -- Caladrius Biosciences, Inc. Nasdaq: CLBS Caladrius or the Company, a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced the appointment of Anne Whitaker to its Board of Directors. Ms. Whitaker is a seasoned healthcare executive bringing to Caladrius 28 years of experience in the life science industry, including senior leadership roles with large pharmaceutical, biotech and specialty pharma companies, and with a proven track record of building and leading high performance teams to successfully commercialize pharmaceuticals, consumer products and medical devices. 